PCO371

Phase 1Small molecule

Roche

PCO371 is one of 19 small molecule programs targeting Hypoparathyroidism. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismActive, not recruiting

HypoparathyroidismPhase 1

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

3 2

Rocaltrol

Alnylam Pharmaceuticals

Approved

—3

Calciferol

Alnylam Pharmaceuticals

Klor-Con

1 5

One-Alpha

Roche

Phase 2

1 6

Forteo

AAlmaject

Phase 2

2 7

Calcium Citrate

CCampus Bio-Medico University

Approved

1 8

Tums

Otsuka

Phase 2

1 9

Rhpth

Takeda

Phase 3

5 10

Transcon Hgh

VVisen Pharmaceuticals (Shanghai) Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoparathyroidism1 trial

A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism

Terminated· Roche logo

Roche·Phase 1·NCT04209179·5 enrolled

Metabolism1 trial

Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371

Completed· Roche logo

Roche·Phase 1·NCT04649216·11 enrolled

Single Ascending Dose1 trial

A Single Ascending Dose Study of PCO371 in Healthy Volunteers

Terminated· Roche logo

Roche·Phase 1·NCT02475616·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PCO371. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PCO371 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PCO371. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

PCO371

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoparathyroidism1 trial

Metabolism1 trial

Single Ascending Dose1 trial

References

Drug Info

Quick Facts

Related News